Our FAK inhibitor for the treatment of melanoma is now in preclinical testing

Exciting News from FAKnostics!

Our cutting-edge FAK inhibitor is making strides in the fight against melanoma, particularly in patients with NRAS mutation. Currently in preclinical testing, our inhibitor showcases exceptional pharmacokinetics and showcases remarkable efficacy in inhibiting tumor growth in vivo. We are proud to contribute to the advancement of melanoma treatment and remain committed to developing innovative solutions for patients in need. Stay tuned for more updates on our groundbreaking research!